Raptor Pharmaceutical (RPTP) : 5 analysts are covering Raptor Pharmaceutical (RPTP) and their average rating on the stock is 1.8, which is read as a Buy. 3 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 2 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Raptor Pharmaceutical (RPTP) : Average target price received by Raptor Pharmaceutical (RPTP) is $7.6 with an expected standard deviation of $2.7. The most aggressive target on the stock is $11, whereas the most downbeat target is $4. 5 financial analysts are currently covering the stock.
For the current week, the company shares have a recommendation consensus of Buy.
Raptor Pharmaceutical (NASDAQ:RPTP): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $5.91 and $5.83 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $6.17. The buying momentum continued till the end and the stock did not give up its gains. It closed at $6.17, notching a gain of 3.87% for the day. The total traded volume was 872,504 . The stock had closed at $5.94 on the previous day.
Raptor Pharmaceutical Corp. is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The Companys product, PROCYSBI delayed-release capsules received marketing approval from the FDA for the management of nephropathic cystinosis in adults and children six years and older. In Europe, PROCYSBI gastro-resistant hard capsules of cysteamine, received a marketing authorization from the European Commission (EC), as an orphan medicinal product for the management of nephropathic cystinosis in the European Union (EU). The Companys pipeline includes its delayed-release form of cysteamine, or RP103 and its oral 4-methylpyrazole, or Convivia. Its other product, Quinsair, is an inhaled formulation of levofloxacin used for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.